Lanabecestat
| |
| Names | |
|---|---|
| Systematic IUPAC name
4-Methoxy-5''-methyl-6'-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2''-imidazole]-4''-amine | |
| Other names
LY3314814
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChemSpider | |
CompTox Dashboard (EPA)
|
|
| |
| |
| Properties | |
| C26H28N4O | |
| Molar mass | 412.537 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
AZD3293, also known as LY3314814 is an oral beta-secretase 1 cleaving enzyme (BACE) inhibitor. A BACE inhibitor in theory would prevent the buildup of beta-amyloid and may help slow or stop Alzheimer's disease.
In September 2014 AstraZeneca and Eli Lilly and Company announced an agreement to codevelop AZD3293.[1] A pivotal Phase II/III clinical trial of AZD3293 started in late 2014 and is planned to recruit 1,500 patients and end in May 2019.[2] In April 2016 the company announced it would advance to phase 3 without modification.[3]
See also
References
- ^ "AstraZeneca and Lilly announce alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer's disease". www.astrazeneca.com. 16 Sep 2014. Retrieved 8 Oct 2014.
- ^ "AstraZeneca and Lilly move Alzheimer's drug into big trial". December 2014.
- ^ Lilly and AstraZeneca Alzheimer's candidate advances; AstraZeneca earns $100M milestone. April 2016
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |